- Company
- Surveillance or global standard? Dispute over SAP by MSD
- by Jun 11, 2020 06:22am
- The employees of MSD Korea are strongly opposing against the management planning to implement tightened self-assurance program (SAP) guideline. The company’s sales department is infuriated with the Korean management adhering to the global standard, regardless of the employees constantly demanding for flexible amendment. According to the
- Company
- HPV vaccine Gardasil9 eligible age to extend up to 45
- by Eo, Yun-Ho Jun 10, 2020 06:12am
- The vaccination eligible age for the human papillomavirus (HPV) vaccine Gardasil9 would be extended in Korea as well. Pharmaceutical industry sources reported, MSD has submitted an indication extension application to Ministry of Food and Drug Safety (MFDS) to vaccinate both female and male in age 27 to 45. The approval may be cleared in
- Company
- Medtronic Korea joined the KDPU
- by An, Kyung-Jin Jun 10, 2020 06:09am
- A union was established in Medtronic Korea, an Irish medical device company. According to the industry on the 9th, Medtronic Korea recently launched an in-house union and joined the new branch of the Korea democratic Pharmaceutical Unions. The union was founded on May 28th. The union sent official letters to the company to formalize the es
- Company
- Labor union protests against Lundbeck Korea for 50 days
- by An, Kyung-Jin Jun 10, 2020 06:09am
- The conflict is deepening between Lunbeck Korea and employees regarding a recent layoff. On June 8, the Lunbeck Korea Chapter of Korea Democratic Pharmaceutical Union protested in front of the company’s head office in Songpa-gu, Seoul. Denouncing the unfair labor practice by the company management, the labor union has been picketing o
- Company
- Accelerating the market entry of JAK inhibitors
- by Kim, Jin-Gu Jun 10, 2020 06:08am
- JAK inhibitors, oral rheumatoid arthritis drugs, are increasing sales in the autoimmune disease treatment market. However, the major item Xeljanz (Tofacitinib) is faltering. For the first time, quarterly sales fell. It is an analysis that the growth of Olumiant(Baricitinib) had an effect. In addition, generics such as Smyraf (Peficitin
- Company
- Rinvoq was approved in Korea
- by Eo, Yun-Ho Jun 9, 2020 06:28am
- Domestic market competition among JAK inhibitors is fierce. According to the related industry, Pfizer's Xeljanz (Tofacitinib), Lilly's Olumiant (Baricitinib), Astellas' Smyraf(Peficitinib) and Abbvie’s Rinvoq (Upadacitinib) were approved on the 4th. Rinvoq's permission is based on five phase III SELECT clinical trials (SELECT-NEXT, SEL
- Company
- Will COVID-19 Vaccine be specially imported?
- by Kim, Jin-Gu Jun 9, 2020 06:26am
- The government is reviewing the vaccine being developed by AstraZeneca as a special import for COVID-19. Although it is still in the development stage, it is said that the government and the company had contacted with the plan to urgently introduce it in the form of special import if the clinical trial succeeds. According to the pharmaceutic
- Company
- Customized Rx considering the patient's condition is needed
- by Eo, Yun-Ho Jun 8, 2020 06:13am
- The need for patient-specific prescriptions is emerging in the field of obesity treatment. At the recently held 'Saxenda e-Class' (Saxenda.livesympo.com), Professor Hye Jin Chun of the dept. of Family Medicine at Cha University Bundang Medical Center had a time to cover information about treatment for obesity. On this day, Professor Hye J
- Company
- Celltrion, begins development of Insulin pen biosimilar
- by An, Kyung-Jin Jun 8, 2020 06:11am
- Celltrion is working with a domestic medical device company to develop an insulin biosimilar. The goal is to secure cost competitiveness and lower dependence on imports by developing a pen-type insulin injection for the first time in Korea. Celltrion’s insulin pipeline was selected as a state-designated project by the Korea Evaluation Ins
- Company
- Unpredictable Cancer Committee make all kinds of decisions
- by Eo, Yun-Ho Jun 5, 2020 06:10am
- The expression on all the pharmaceutical companies accepting the final outcome varied as the meeting concluded. But for sure, no one had a perfect game. On June 3, Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee was convened to discuss two immunotherapies, two poly ADP-ribose polymerase (PARP) inhibiting t
